Reata Pharmaceuticals
Reata Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 2008, Reata focuses on developing innovative therapies for serious diseases, particularly in the fields of neurology and rare diseases. The company is renowned for its unique product offerings, including its lead drug, which targets critical pathways in cellular metabolism. Reata's commitment to advancing treatment options has positioned it as a leader in the market, achieving notable milestones in clinical development and regulatory approvals. With a strong emphasis on scientific innovation, Reata Pharmaceuticals continues to make strides in improving patient outcomes and addressing unmet medical needs.
DitchCarbon Score
How does Reata Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Reata Pharmaceuticals's score of 3 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Reata Pharmaceuticals's reported carbon emissions
Reata Pharmaceuticals, headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments in detail. However, the absence of documented reduction initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly prioritises sustainability, Reata Pharmaceuticals may need to establish clear climate goals and reporting practices to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Reata Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
